While emerging therapies for mantle cell lymphoma (MCL) continue to shape the treatment landscape, no key standard currently exists, says one expert – particularly for older patients, who benefit most from a treatment approach that has been tailored to fit them and their disease.
In an interview with CURE’s sister publication, OncLive, Peter Martin of Weill Cornell Medicine, explained how an individualized approach that takes a number of factors into consideration benefits older patients with MCL.
View more at [ Ссылка ]
CURE: Combining science and humanity to make cancer understandable.
